We're posting up notes from the Sohn New York Investment Conference. Next up is Bihua Chen of Cormorant Asset Management who presented a long of Reata Pharmaceuticals (RETA).
Bihua Chen's Sohn New York Presentation
• Reata pharmaceuticals (RETA) - stock can be a ten bagger if it works. Has an experimental drug targeting kidney disease with good results. Can be a $25 billion company on $5 billion peak sales. Current market cap is $2.3 billion
• Current data is so good that some people believe the data is fake
• Some safety concerns on heart safety (now excluding patients with heart disease and slowly moving patients dose up) Since changes there have been no problems. No liver problems or any warning signs. No actual muscle loss. They think the safety profile is good
Be sure to check out the rest of the Sohn New York conference presentations.
Tuesday, May 7, 2019
Bihua Chen Long Reata Pharmaceuticals: Sohn New York Conference
blog comments powered by Disqus
